Haemonetics Price To Book vs. Net Income
The gap between Haemonetics' market value and book value reflects how the market perceives future potential versus historical cost. Haemonetics' market capitalization is 2.74 B. Haemonetics P/B of 2.99 shows the market assigns a modest premium over accounting equity. Enterprise value stands at 3.58 B. The relationship between Haemonetics' intrinsic value, market price, and book value adds depth to the analysis.
Haemonetics' estimated value and market price are complementary but separate measures of worth. Haemonetics' trading price represents the transaction level agreed by market participants.
Haemonetics Net Income vs. Price To Book Fundamental Analysis
Comparative market metrics assess Haemonetics's pricing relative to peers. Haemonetics holds the #2 position for price to book relative to top peers. It also holds the #2 position for net income relative to top peers with a Net Income-to-Price To Book ratio near 56,140,016 . Valuation multiples such as P/E, P/B, and P/S compare Haemonetics to peer earnings performance.Haemonetics Net Income vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Haemonetics |
| = | 2.99 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Haemonetics |
| = | 167.68 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Haemonetics Net Income Comparison
Haemonetics is currently under evaluation for net income relative to top peers.
Haemonetics Profitability Projections
A key trait of a strong company is its ability to earn a profit, and for Haemonetics investors this matters a lot. Profit progress for Haemonetics blends several ratios, where stable trends suggest steady results. Haemonetics currently maintains a profit margin of 13.3%. A rising operating margin signals that Haemonetics' core business is getting more efficient. The operating margin stands at 21.0% while return on equity is 19.3%. The profit trend below reflects Haemonetics' results across the most recent reporting periods. Recent net income of 167.7 M reflects the bottom-line result of these profitability dynamics.
Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people.
Haemonetics Profitability Driver Comparison
Profitability drivers are factors that directly affect the investment outlook for Haemonetics. Investors holding Haemonetics' stock face unpredictable events that can materially affect the company's earnings.
Earnings per Share Projection vs Actual
Use Haemonetics in pair-trading
Pair analysis around Haemonetics matters because it can turn one security idea into a more market-neutral structure. Used properly, pair trading is less about prediction in isolation and more about identifying relative mispricing between related positions.
Haemonetics Pair Trading
Haemonetics Pair Trading Analysis
Finding closely correlated positions to Haemonetics provides context for tax-loss harvesting analysis. Selling Haemonetics at a loss and repurchasing it immediately would violate IRS wash-sale rules.
The correlation of Haemonetics is a statistical measure of how it moves in relation to other instruments. Values near +1 indicate near-identical movement to Haemonetics, while values near -1 suggest inverse movement.
Pair evaluation and Correlation analysis for Haemonetics provide hedging context. The information reflects structured market data collected across trading periods.Use Investing Themes to Complement your Haemonetics position
With 2.74 Billion market cap in the Medical Instruments & Supplies industry, Haemonetics works well as a smaller-cap core holding around which broader thematic baskets can be built. Haemonetics smaller-cap scale (2.74 Billion) within Medical Instruments & Supplies helps compare substitutes, complements, and diversifiers that strengthen the overall Healthcare allocation.
Did You Try This Idea?
Run Latest Gainers Thematic Idea Now
Latest Gainers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 0 constituents at this time.
Whether used as a passive allocation or an active trading idea, the Latest Gainers Theme provides a structured starting point for portfolio construction.
| View All Next | Launch |